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Abstract
Grape seed proanthocyanidins (GSP) have been
shown to inhibit skin chemical carcinogenesis and
photocarcinogenesis in mice. The mechanisms
responsible for the anticarcinogenic effects of GSP
are not clearly understood. Here, we report that
treatment of JB6 C141 cells (a well-developed cell
culture model for studying tumor promotion in kerati-
nocytes) and p53+/+ fibroblasts with GSP resulted in a
dose-dependent induction of apoptosis. GSP-induced
(20–80 g/ml) apoptosis was observed by using immu-
nofluorescence (27–90% apoptosis) and flow cytometry
(18–87% apoptosis). The induction of apoptosis by
GSP was p53-dependent because it occurred mainly in
cells expressing wild-type p53 (p53+/+; 15–80%) to a
much greater extent than in p53-deficient cells (p53/;
6–20%). GSP-induced apoptosis in JB6 C141 cells was
associated with increased expression of the tumor-
suppressor protein, p53, and its phosphorylation at
Ser15. The antiapoptotic proteins, Bcl-2 and Bcl-xl,
were downregulated by GSP, whereas the expression
of the pro-apoptotic protein, Bax, and the levels of
cytochrome c release, Apaf-1, caspase-9, and cleaved
caspase 3 (p19 and p17) were markedly increased in
JB6 C141 cells. The downregulation of Bcl-2 and
upregulation of Bax were also observed in wild-type
p53 (p53+/+) fibroblasts but was not observed in their
p53-deficient counterparts. These data clearly demon-
strate that GSP-induced apoptosis is p53-dependent
and mediated through the Bcl-2, Bax, and caspase
3 pathways.
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Introduction
Grape seeds are byproducts of grapes (Vitis vinifera)
formed during the industrial production of grape juice and
wine. They are a potent source of proanthocyanidins, which
are mainly composed of dimers, trimers, and oligomers of
monomeric catechins [1,2], as shown in Table 1. Grape
seed proanthocyanidins (GSP) are potent antioxidants
and are able to serve as free radical scavengers [3]. Their
antioxidant activity is 20 times more potent than vitamin C,
and 50 times more potent than vitamin E [4]. GSP has a
broad spectrum of biologic activities. It is antimutagenic, anti-
inflammatory, antiangiogenic, and anticarcinogenic [5–9]. It
also has cytotoxic effects in diverse cancerous cell lines
[10–12], which is largely mediated through apoptosis with
no adverse biologic effects on the normal cells [13]. The
anticarcinogenic effects of GSP on skin have been shown
in 7,12-dimethylbenz(a)anthracene– initiated and 12-O-
tetradecanoylphorbol-13-acetate–promoted chemical carcino-
genesis in mice [14]. Recently, we have shown that dietary
feeding of GSP to SKH-1 hairless mice significantly inhibited
UV radiation– induced skin carcinogenesis in terms of tumor
incidence, tumor multiplicity, and tumor size [6]. Dietary feed-
ing of GSP also inhibited UV-induced malignant conversion
of papillomas to carcinomas [6]. Long-term feeding of mice
with GSP did not have any apparent signs of toxicity [6].
These observations indicated that GSP has a strong inhib-
itory effect on the tumor promotion/progression stage of
multistage carcinogenesis [6,14].
p53 is a tumor-suppressor gene whose product can act as a
suppressor of transformation [15] and has been shown to be
induced by DNA damage [16]. In turn, p53 orchestrates a
global transcriptional response that either counters cell prolife-
ration or induces apoptosis [17]. GSP has been shown to
protect against stress-induced changes in the expression of
p53 and the antiapoptotic protein, Bcl-2, in human oral epithe-
lial [18] and liver cells [3]. The Bcl-2 family of proteins consists
of pro- and antiapoptotic regulators of programmed cell death/
apoptosis. The established mode of action of each separate
entity is to either protect or disrupt mitochondrial integrity,
thereby activating or inhibiting the release of downstream
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factors such as cytochrome c from the mitochondrion,
which stimulates apoptosis. The Bax gene is an apoptosis-
promoting member of the Bcl-2 gene family. The Bcl-2
protein is known to form heterodimers with the Bax protein
in vivo and the molar ratio of Bcl-2 to Bax determines
whether apoptosis is induced or inhibited in target tissues
[19]. The Bax protein is considered to be one of the primary
targets of p53 and controls cell death through its participa-
tion in the disruption of mitochondria with the subsequent
release of cytochrome c [20]. Cytochrome c release, in turn,
activates caspases 9 and 3 [21]. Cleaved caspase 3
(p17kDa and p19kDa) is regarded as a proximate mediator
of apoptosis.
Inhibition of skin tumor formation in both chemical carcino-
genesis and photocarcinogenesis in the skin by GSP has
been associated with its chemopreventive effects during the
tumor promotion stage [6,14]; however, the molecular mech-
anisms associated with this activity are not clearly under-
stood. We therefore initiated studies to determine whether
GSP induced apoptosis in preneoplastic epidermal keratino-
cytes and, if so, whether p53, the Bcl-2 family of proteins,
and caspases were involved in the process. To do this, we
examined the effect of GSP on the preneoplastic epidermal
cell line, JB6 C141, which is a well-developed and excellent
cell culture model for studying tumor promotion [22,23].
Treatment of these cells with the tumor promoter 12-O-
tetradecanoylphorbol-13-acetate or other tumor promoters
resulted in profound morphologic changes, mitogenic
stimulation, and tumorigenesis in nude mice—all hallmarks
of transformation to tumor cell phenotype [22,23]. Pre-
neoplastic epidermal JB6 C141 cells have been successfully
used for the determination of mechanistic pathways involving
p53, Bcl-2, Bax, and caspases with chemopreventive
agents [24,25]. Our data obtained from this study show
that GSP induce apoptosis through their effects on p53
and several p53-dependent proteins.
Materials and Methods
Chemicals, GSP, and Antibodies
Purified GSP were obtained for this study as a generous
gift from Kikkoman Corporation (Noda, Japan). The chemical
composition of GSP was analyzed by Kikkoman Corporation
and is given in Table 1. Dulbecco’s modified Eagle’s medium
(DMEM), penicillin, streptomycin, fetal bovine serum (FBS),
and trypsin/EDTA were purchased from CellGro (Herndon,
VA). Acrylamide and the protein assay kit were obtained from
Bio-Rad (Hercules, CA). Hoechst 33342 and Annexin V–
conjugated Alexa Fluor 488 Apoptosis Detection Kit were
purchased from Molecular Probes, Inc. (Eugene, OR). Anti-
bodies for phospho-p53 (p53 at Ser15), Bcl-xl, Bax, and
cleaved caspase 3 (specific for 17 and 19 kDa) were pro-
cured from Cell Signaling Technology, Inc. (Beverley, MA).
Antibodies for p53, Bcl-2, cytochrome c, apoptotic protease–
activating factor-1 (Apaf-1), caspase 9, and b-actin were
obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA). Enhanced chemiluminescence detection kit for West-
ern blotting was purchased from Amersham Pharmacia
Biotechnologies (Piscataway, NJ). All other chemicals
employed in this study were of analytical grade and pur-
chased from Sigma Chemical Co. (St. Louis, MO).
Cell Lines and Culture Conditions
The JB6 C141 preneoplastic mouse epidermal cell line
was cultured in monolayers with DMEM supplemented
with 10% (vol/vol) heat-inactivated FBS and glutamine
(2 mM) at 37jC in a humidified atmosphere of 5% CO2.
p53+/+ and p53/ mouse embryonic fibroblast cells were
cultured in DMEM supplemented with 15% FBS and
glutamine (2 mM) at 37jC in a humidified atmosphere of
5% CO2. For all the experiments, JB6 C141 cells, p53
+/+
fibroblast, and p53/ fibroblast cells were serum-starved
in 0.5% FBS/DMEM overnight and thereafter treated with
GSP for 24 hours.
Cell Viability Assay
The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyltetra-
zolium bromide) assay was performed to determine the
effect of GSP on the cellular proliferation and viability of
JB6 C141, p53+/+, and p53/ cells as described previously
with some modifications [26,27]. Briefly, approximately 1 
104 cells/well were plated in 96-well plates and kept in the
incubator at 37jC using previously described cell culture
conditions. After overnight incubation to allow them to ad-
here, the cells were treated with varying concentrations of
GSP (0–100 mg/ml) in fresh media for 12, 24, and 48 hours.
Each treatment and time point was assayed in at least eight
replicates. At the stipulated time following treatment with
GSP, medium was aspirated and MTT (50 ml of a 5 mg/ml
stock solution in PBS) was added in each well of the 96-well
culture plate. Incubation was continued at 37jC for an
additional 2 hours. At that time, the plates were spun, super-
natants were discarded, and purple-colored precipitates of
formazan were dissolved in 150 ml of dimethyl sulfoxide. The
color absorbance of each aliquot was recorded at 540 nm
with a Bio-Rad 3350 microplate reader with a reference at
650 nm serving as a blank. The reduction in viability of cells
in each well was expressed as the percentage compared to
non–GSP-treated control cells.
Table 1. Chemical Composition of GSP Used in This Study.
Constituents Total GSP (%)
Total proanthocyanidins 89.3
Dimers 6.6
Trimers 5.0
Tetramers 2.9
Oligomers 74.8
Total monomeric flavanols 6.6
(+)-Catechin 2.5
()-Epicatechin 2.2
()-Epigallocatechin 1.4
()-Epigallocatechin-3-gallate 0.5
Moisture 2.2
Protein 1.1
Ash 0.8
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Detection of Apoptotic Cells by ImmunofluorescenceStaining
Cells were treated for 24 hours with GSP (20–80 mg/ml)
and were then washed with PBS, after which they were
fixed in freshly prepared 0.1% ice-cold paraformaldehyde
for 10 minutes. The cells were then washed twice with PBS
and stained with Hoechst 33342 (50 mg/ml) for 1 minute in the
dark. Morphologic changes were observed using fluorescent
microscopy in a blinded manner, the percentage of apoptotic
cells was scored by counting at least 200 cells per treatment
group, and the average percentage of apoptotic cells was
determined for each treatment group. The experiment was
repeated at least three times.
Quantification of Apoptotic Cells by Flow Cytometry
Induction of apoptosis by GSP treatment was further
quantified using the Annexin V–Alexa Fluor 488 Apoptosis
Detection kit following the manufacturer’s protocol. Briefly,
JB6 C141 cells, p53+/+ fibroblast, or p53/ fibroblast cells
were treated with GSP (20–80 mg/ml) or without GSP for
24 hours. Cells were harvested, washed with cold PBS,
and subjected to Annexin V and propidium iodide (PI) stain-
ing in binding buffer at room temperature for 15 minutes in
the dark. Stained cells were analyzed by fluorescence-
activated cell sorting (FACSCalibur; BD Biosciences, San
Jose, CA) using CellQuest 3.3 Software. In this apoptotic
assay kit, recombinant Annexin V conjugated to Alexa Fluor
488 fluorescent dye was used, which enhanced its sensitiv-
ity. The apoptotic cells stained with Annexin V showed
green fluorescence and were present in the lower right
(LR) quadrant of the histogram. The cells stained with both
Annexin V and PI showed red and green fluorescence,
and were present in the upper right (UR) quadrant of the
FACS histogram.
Preparation of Cell Lysates, Immunoprecipitation,
and Western Blotting
Following treatment of JB6 C141, p53+/+ or p53/ fibro-
blasts were incubated with or without GSP at the required
concentrations for 24 hours. The cells were harvested,
washed twice with cold PBS (10 mM, pH 7.4) and lysed with
ice-cold lysis buffer (50 mM Tris–HCl, 150 nM NaCl, 1 mM
EGTA, 1 mM EDTA, 1% NP-40, 1 mM sodium orthovana-
date, 20 mM NaF, 1 mM PMSF, 10 mg/ml aprotinin, and
10 mg/ml leupeptin, pH 7.4) for half an hour over ice, as
described previously [28]. The lysate was then collected in a
microfuge tube and passed through a 21-gauge needle to
break up the cell aggregates. The lysate was cleared by
centrifugation at 14,000 rpm for 10 minutes at 4jC and the
supernatant was used for Western blot analysis at that time
or was stored at80jC for future use. The lysates containing
200 mg of protein were immunoprecipitated using a mono-
clonal mouse IgG antibody against p53 and rotated overnight
at 10 cycles/min at 4jC. Thereafter, protein A/G plus aga-
rose beads were added and continuously rotated for another
3 hours at 4jC. The beads were washed three times with
PBS and were examined for phosphorylated p53 protein
(Ser15). The protein concentration was determined by the
DC Bio-Rad assay using the manufacturer’s protocol. For
Western blot analysis, proteins (30–50 mg) were resolved on
10–14% sodium dodecyl sulfate polyacrylamide gel and
transferred onto a nitrocellulose membrane. Themembranes
were treated with blocking buffer (5% nonfat dry milk in 0.1%
Tween 20 in 20 mM Tris-buffered saline, pH 7.5) by incu-
bating them for 1 hour at room temperature. This was
followed by incubation with the appropriate primary antibody
(at the dilutions recommended by the manufacturer) in
blocking buffer overnight at 4jC. The blot was then washed
with PBS and then was incubated with the appropriate
secondary antibody conjugated with horseradish peroxidase
at room temperature for 1 hour. Protein bands were then
visualized using the ECL detection system (Amersham Life
Science, Inc., Piscataway, NJ). Autoradiography was per-
formed with XAR-5 film (Eastman Kodak Co., Rochester,
NY). To verify equal protein loading and transfer, the blots
were stripped and reprobed for b-actin using an antiactin
rabbit polyclonal antibody and, thereafter, the same protocol
was followed as detailed above. To compare the relative
intensity of each protein band from different groups in
Western blot, computerized densitometry was performed
using OPTIMAS 6.2 software program.
Statistical Analysis
The Student’s t test was performed to determine the
statistical significance of the difference in the absolute values
of the apoptotic cell death between the GSP-treated and
non–GSP-treated groups. The GSP-induced apoptosis was
considered significant at P < .05 where not mentioned.
Results
GSP Treatment Decreases Cell Viability in JB6 C141 Cells
A preliminary screening test was performed to assess the
effect of GSP on cellular proliferation and viability at different
time points using the MTT assay. As shown in Figure 1, there
was a dose- and time course–dependent reduction in the
viability of JB6 C141 cells treated with GSP (20–80 mg/ml).
Treatment with GSP for 12 hours did not result in a significant
Figure 1. GSP inhibits the proliferation and cell viability of preneoplastic
epidermal JB6 C141 cells in a dose-dependent manner. Dose-dependent
effect of GSP on the viability of JB6 C141 cells was determined by the MTT
assay as described in the Materials and Methods section. Data are presented
in terms of the mean ± SD of eight replicates. *P < .01 vs control (non-GSP);
**P < .001 vs control (non-GSP).
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reduction in cell viability, whereas with 24 hours of treatment,
a significant reduction in cell viability (16–81%, P < .01–
.001) was observed. The cell viability decreased even further
when cells were incubated with GSP for 48 hours (20–88%).
Because the cell viability of JB6 C141 cells was significantly
decreased by GSP after 24 hours of its treatment, we
selected this particular time point for further studies.
GSP Treatment Induces Apoptosis in JB6 C141 Cells
To determine the effect of GSP treatment on the induction
of apoptosis in JB6 C141 cells, immunofluorescence staining
was performed to detect the number of apoptotic cells
(Figure 2). At doses of 20, 40, 60, and 80 mg/ml GSP, a
significant increase in apoptosis of JB6 C141 cells was
observed, which ranged from 21% to 90% (P < .01–.001).
We further confirmed our observations using flow cytometry.
In this assay, cells were stained with Annexin V–conjugated
Alexa Fluor 488 dye (which was used to detect apoptotic
cells with externalized phosphatidyl-serine leaflets) and PI.
The cells in the lower right quadrant of the histogram (LR;
Figure 3) represent the number of early apoptotic cells.
Those in the upper right (UR; Figure 3) quadrant represented
the cells in late apoptosis, which had taken up both Alexa
Fluor 488 and PI [25,27]. We found that treatment with GSP
(20–80 mg/ml) for 24 hours increased the number of early
apoptotic cells from 9.5% to 15.4% in a dose-dependent
manner compared to only 2.8% of early apoptotic cells in the
non–GSP-treated (control) group. The number of late apo-
ptotic cells (in UR quadrant) also increased from 4.3% in the
untreated control group to 71.9% at the highest GSP dose
level (80 mg/ml). The total percentage of apoptotic cells (UR +
LR) increased from 7.1% in the control group to 87.3% with
80 mg/ml GSP treatment.
GSP Treatment Upregulates p53 Expression with
a Concomitant Increase in Phosphorylation of p53 in
JB6 C141 Cells
p53 protein plays a pivotal role in the suppression of
transformation [15]. Activation of p53 tumor-suppressor
functions is critically dependent on the phosphorylation at
the Ser15 residue [29]. To determine the role of p53 in the
induction of apoptosis by GSP treatment in JB6 C141 cells,
which express wild-type p53, we assessed total p53 protein
levels and phosphorylated p53 at Ser15 by Western blot
analysis. We observed a significant increase in the basal
level of p53 protein (Figure 4, upper panel ) as well as a
concomitant increase in its phosphorylation (Figure 4, lower
panel ) in a dose-dependent manner with GSP treatment
(20–80 mg/ml). The increase in p53 after GSP treatment may
be because of its stability and/or activation.
p53-Deficient (p53/) Cells Are Resistant to
GSP-Induced Apoptosis
Similar to JB6 C141 cells, the effect of GSP on cell
viability of p53+/+ and p53/ cells was determined using
MTT assay. There was no significant inhibition in cell viability
of p53+/+ and p53/ cells observed after 12 hours of GSP
treatment. However, treatment of GSP at doses of 20, 40,
Figure 2. GSP induces apoptosis in JB6 C141 cells. Apoptosis was
determined by immunofluorescence staining as detailed in the Materials and
Methods section. Briefly, cells were treated with GSP for 24 hours; thereafter,
morphologic changes in JB6 C141 cells undergoing apoptosis were observed
under fluorescence microscopy. Cells were treated without GSP (panel A) and
with GSP (panels B, C, D, and E for 20, 40, 60, and 80 g/ml, respectively) for
24 hours after overnight serum starvation. The number of apoptotic cells
induced with or without GSP treatment is summarized in panel F. The
experiment was repeated two times and the average percentage of apoptotic
cells ±SD for each treatment group is indicated. At least 200 cells were counted
in a blinded manner to score the percentage of apoptosis in each treatment
group. *P < .01 vs control (non-GSP); **P < .001 vs control (non-GSP).
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60, and 80 mg/ml to p53+/+ cells for 24 hours resulted in a
dose-dependent inhibition of cell viability (14 ± 4% to 76 ±
8%) compared to that of non–GSP-treated control cells. The
cell viability of p53+/+ cells was further decreased after
48 hours of GSP treatment (20–84%). In contrast, the
inhibition of cell viability in p53-deficient (p53/) cells was
not as much as in p53+/+ cells with GSP (20–80 mg/ml)
treatment after 12, 24, or 48 hours. The inhibition of cell
viability in p53/ cells ranged from 6% to 16%.
To obtain more definitive evidence that p53 is required for
the induction of apoptosis by GSP, the effect of GSP on a
fibroblast cell line derived from p53-deficient (p53/) mouse
embryos and their wild-type p53+/+ counterpart was exam-
ined. p53+/+ (wild-type) cells treated with increasing doses of
GSP exhibited a dose-dependent increase in the number of
cells undergoing apoptosis, which ranged from 35% to 79%
compared to 15% in non–GSP control cells, as detected
by morphologic methodology (Figure 5, panels A–E ). The
degree to which p53+/+ fibroblasts underwent apoptosis was
further quantitated by flow cytometry. The number of cells in
the GSP-induced early phase of apoptosis ranged from
29.3% to 52.7% after 24 hours of GSP treatment compared
to only 18.9% in the non–GSP-treated group. Similarly,
there was a dose-dependent increase in cells in the late
phase (UR) of apoptosis. The total number of cells undergo-
ing apoptosis after GSP treatment was 33.2% to 77.9%
compared to 22.9% in the non-GSP control group.
Figure 3. GSP-induced apoptosis in JB6 C141 cells was determined by the
flow cytometry using Annexin V–Alexa Fluor 488 Apoptosis Vybrant Assay
kit. Cells were incubated with Annexin V–conjugated Alexa Fluor 488 and
PI in binding buffer at room temperature following the manufacturer’s
protocol. Panel A indicates the control cells (non-GSP treatment). The cells
in panels B, C, D, and E were treated with 20, 40, 60, and 80 g/ml GSP
for 24 hours after overnight serum starvation as detailed in Materials and
Methods section. LR (lower right) quadrant depicts the percentage of early
apoptotic cells (Annexin V–stained cells) and the UR (upper right)
quadrant depicts the percentage of late apoptotic cells (Annexin V+PI–
stained cells).
Figure 4. GSP increases p53 level and induces phosphorylation of p53 at
Ser15 in JB6 C141 cells. Serum-starved JB6 C141 cells were treated with
varying doses of GSP (20–80 g/ml) for 24 hours. Cell lysates were prepared
from these cells, and 200 g of proteins was used for immunoprecipitation to
detect the phosphorylation of p53 at Ser15 using a specific antibody, as
described in Materials and Methods section. The same blot was stripped and
reprobed using an antibody against total p53. -Actin was used as an internal
control to monitor the equal loading and transfer of proteins from gels to
membranes. Relative intensity of the bands was determined and is shown
below the blots. Experiments were repeated three times and a representative
blot is shown.
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Figure 5. GSP induces significantly less apoptosis in p53-deficient (p53/) cells compared to p53 wild-type (p53+/+) cells. Both p53+/+ and p53/ fibroblast cells
were cultured under identical conditions as was done in JB6 C141 cells except that the cells were treated with 15% FBS in DMEM. Cells were starved in 0.5% FBS/
DMEM overnight and thereafter treated with GSP in serum-containing media for another 24 hours. Morphologic changes in p53+/+ and p53/ fibroblast cells
undergoing apoptosis were observed under fluorescence microscopy. Cells in panels A and G were not treated with GSP (controls), whereas increasing
concentrations of GSP were added to cultures for 24 hours after overnight serum starvation in panels B–E and H–K by 20, 40, 60, and 80 g/ml, respectively. The
percentage of apoptotic cells from panel A to panel E is summarized in panel F, and the percentage of apoptotic cells from panel G to panel K is summarized in
panel L. The experiment was repeated at least two times and the average percentage of apoptotic cells ± SD for each treatment group is indicated. At least 200
cells were counted in a blinded manner to score the percentage of apoptosis in each treatment group. *P < .01 vs control (non-GSP); **P < .005 vs control (non-
GSP); ***P < .001 vs control (non-GSP).
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Having ascertained that p53+/+ fibroblasts responded to
GSP in a manner that was similar to JB6 C141 cells, we eval-
uated the effect of treatment with GSP on the p53-deficient
(p53/) fibroblast cell line. At none of the dose levels
employed did p53/ achieve a level of apoptosis that was
comparable to that seen in the p53+/+ counterparts (Figure 5).
It should be noted that p53/ fibroblasts did undergo
some apoptosis at the two highest treatment levels (60 and
80 mg/ml) (Figure 5, panels J and K ), but even at these
doses, the level of apoptosis was not nearly as great as in the
p53+/+ fibroblasts. The resistance of p53/ cells to apopto-
sis by GSP was confirmed by flow cytometry (Figure 6,
panels F–J ). The percentage of cells undergoing early (LR
quadrants) and late (UR quadrants) apoptosis was increased
only at the 60 and 80 mg/ml GSP doses. The total number of
apoptotic cells was only 17.4% at the maximum dose of GSP
(80 mg/ml), which is significantly less than that induced by
GSP in the p53+/+ cells (77.9%, P < .005).
GSP Treatment Downregulates Antiapoptotic Proteins,
Bcl-2 and Bcl-xl, with a Concomitant Increase in
Pro-Apoptotic Protein, Bax, in JB6 C141 Cells
The Bcl-2 and Bcl-xl proteins inhibit programmed cell
death and are associated with cell survival. Their expression
corresponds with the p53 status of the cells. Bax is another
pro-apoptotic member of this family, which increases apo-
ptosis in cells [19,30,31]. We therefore reasoned that if p53
was involved in GSP-induced apoptosis, there would be
decreased expression of Bcl-2 and Bcl-xl and increased
expression of Bax proteins in GSP-treated JB6 C141 cells.
Compared with control non–GSP-treated cells, treatment of
JB6 C141 cells with GSP resulted in a dose-dependent
decrease in the levels of Bcl-2 expression. GSP treatment
at the 60 and 80 mg/ml doses resulted in >90% inhibition of
Bcl-2 (Figure 7, panel A). GSP treatment also induced a
dose-dependent reduction in the levels of Bcl-xl protein, with
nearly 100% inhibition at the 80 mg/ml GSP dose (Figure 7,
panel D). The level of pro-apoptotic Bax protein was corre-
spondingly upregulated from 1.3- to 3.1-fold with increasing
doses of GSP (Figure 7, panel B). Importantly, the ratio of
Bax/Bcl-2 protein expression after GSP treatment was dose-
dependently increased by several folds (panel C), which
indicated the susceptibility of JB6 C141 cells toward under-
going apoptosis.
GSP Treatment Induces Cytochrome c Release, Induction
of Apaf-1, and Activation of Caspases in JB6 C141 Cells
Cellular apoptosis may involve the disruption of mitochon-
drial function through the release of cytochrome c from
mitochondria into the cytosol. Cytosolic cytochrome c can
bind to Apaf-1 and activate caspase 9 in the apoptosome in
response to diverse inducers of cell death, which may lead
to the activation of caspase-3, which subsequently leads to
apoptosis [32–34]. For better understanding and an insight
on the role of these proteins, we determined whether induc-
tion of apoptosis in JB6 C141 cells by GSP is associated with
disruption of mitochondrial function and activation of cas-
pases. Treatment of JB6 C141 cells with GSP (20–80 mg/ml)
resulted in a dose-dependent increase in cytochrome c
release from mitochondria (Figure 8, panel A), induction of
Apaf-1 (Figure 8, panel B), and activation of caspase 9
(Figure 8, panel C) and caspase 3 (Figure 8, panel D)
compared to non–GSP-treated control cells. Activated or
cleaved caspase-3 (17 and 19 kDa) is considered as one of
the key executioners of apoptosis. Because cleaved cas-
pase 3 antibody only recognizes the cleaved products of
caspase 3 (17 and 19 kDa), the original basal level of
uncleaved caspase 3 was not detected in the blot.
GSP Treatment Downregulates Antiapoptotic Protein,
Bcl-2, and Concomitantly Increases Pro-Apoptotic
Protein, Bax, in p53+/+ Cells But Not in p53/ Cells
Finally, we determined whether there was a differ-
ence in Bcl-2, Bcl-xl, and Bax proteins on GSP-induced
apoptosis when p53+/+ and p53/ fibroblast cells were com-
pared. Treatment of GSP decreased the expression of Bcl-2
(4–60%) in p53+/+ cells (Figure 9, left, panel A) but had
virtually no effect in p53-deficient cells (p53/) (Figure 9,
right, panel E ). In contrast to the effects on Bcl-2, Bcl-xl
protein levels were similar in the GSP-treated p53+/+
(left, panel D) and the p53/ (right, panel H ) cells. The lack
of an effect of p53 on Bcl-xl may be the reason why some
p53/ cells underwent apoptosis when higher GSP doses
were given (Figures 5 and 6). Treatment with GSP, which
increased the expression of Bax protein in the p53+/+ cells
(Figure 9, left, panel B), had no effects on its expression in
p53/ cells (Figure 9, right, panel F ). It is important to
mention that the ratio of Bax/Bcl-2 proteins is critical for
apoptosis signal. Here, we found that the ratio of Bax/Bcl-2
was increased by about four-fold in GSP-treated p53+/+ cells
compared to non–GSP-treated p53+/+ cells (Figure 9, panel
C). However, the Bax/Bcl-2 ratio was almost unaffected
after GSP treatment in p53/ cells (Figure 9, panel G).
These observations indicate that p53 may have a role in
regulating the expression of Bcl-2 and Bax proteins after
GSP treatment.
Discussion
Chemoprevention is a promising strategy used to control
the occurrence of cancer. Several botanicals and/or dietary
supplements have been shown to have anticarcinogenic
properties. GSP is one of such dietary botanical supplement,
which has recently been shown to have these properties
[6–12,14]. In vivo animal experiments have shown that
proanthocyanidins from grape seeds possess potent chemo-
preventive effects against the development of skin tumors
[6,14]. However, the molecular mechanisms of anti-
carcinogenic effects in skin are not clearly understood.
Ideally, the chemopreventive agents should be nontoxic
and relatively free of side effects, so they can be adminis-
tered to healthy people for long periods of time. We have
shown that long-term dietary feeding of GSP to animals did
not induce apparent signs of toxicity [6]. GSP has been
shown to have anticancer or cytotoxic activity in in vitro
tumor cells [7–13] and in vivo animal models [6,14,35], while
30 Proanthocyanidins Induce Apoptosis in JB6 C141 Cells Roy et al.
Neoplasia . Vol. 7, No. 1, 2005
Figure 6. GSP induces significantly less apoptosis in p53-deficient cells (p53/) than in p53 wild-type (p53+/+) cells as detected by FACS analysis. Both p53+/+ and
p53/ fibroblast cells were cultured in conditions that were identical to those described in Figure 5 and Materials and Methods section. Cells in panels A and F
were not treated with GSP (controls), whereas cells in panels B–E and G–J were given increasing concentrations of GSP (B–E and G–J by 20, 40, 60, and 80
g/ml, respectively) for 24 hours after overnight serum starvation. The percentage of apoptotic cells was determined by the Annexin V–Alexa Fluor 488 Apoptosis
Vybrant Assay kit following the manufacturer’s protocol. The lower right (LR) quadrant depicts the percentage of early apoptotic cells (Annexin V–stained cells) and
the upper right (UR) quadrant depicts the percentage of late apoptotic cells (Annexin V+PI –stained cells).
Proanthocyanidins Induce Apoptosis in JB6 C141 Cells Roy et al. 31
Neoplasia . Vol. 7, No. 1, 2005
enhancing the growth and viability of the normal cells [13]. In
this study, we found that treatment of GSP resulted in a
reduction of cell viability (Figure 1) and induction of apoptosis
in JB6 C141 cells (Figures 2 and 3). Inhibition of apoptosis is
considered as one of the possible mechanisms of tumor
development and many chemopreventive agents have been
shown to act through the induction of apoptosis to inhibit or
block the carcinogenic process [36–38]. Therefore, our data
indicated that the induction of apoptosis may be one of the
mechanisms for the anticarcinogenic effect of GSP. More-
over, a large volume of evidence indicates that apoptosis
may represent a protective mechanism against neoplastic
development by eliminating genetically damaged cells or
excess cells that have improperly been induced to proliferate
by factors such as carcinogens [39,40].
Normal p53 has been shown to exert its tumor-suppressing
activity by regulating the process of apoptosis [41,42]. This
fact was supported by the findings that p53 is the most
commonly mutated tumor-suppressor gene, and that lack
of p53 expression or function is associated with an increased
risk of tumor formation [43,44]. To investigate the possible
role of p53 in the induction of apoptosis by GSP, we
determined the effect of GSP on JB6 C141 cells and in
p53+/+ and p53/ cell lines. It is evident from our data that
the levels of p53 and its activated/phosphorylated form were
upregulated after GSP treatment and that the induction of
apoptosis by GSP is mediated through this protein. Phos-
phorylation of p53 has been associated with cellular damage
occurring during anticancer therapy [45]. p53 phosphoryl-
ation at Ser15 increases its half-life and thus increases the
accumulation and functional activation of p53 in response to
DNA damage, thereby stabilizing it [46,47]. This information
provides evidence that increase in p53 protein expression
after GSP treatment may be due to increased stability. To
additionally confirm that p53 is involved in GSP-induced
apoptosis, we compared the effect of GSP in wild-type p53
Figure 7. Treatment of GSP decreases the expression of the antiapoptotic proteins, Bcl-2 and Bcl-xl, and increases the expression of the pro-apoptotic protein,
Bax, in JB6 C141 cells. JB6 C141 cells were starved in 0.5% FBS/DMEM overnight and then treated with GSP (20–80 g/ml) in serum-containing media for
another 24 hours. Cell lysates were prepared, and the expression of the proteins was determined by Western blot analysis using the corresponding antibodies, as
detailed in the Materials and Methods section. Relative intensity of bands in each panel was determined. GSP treatment to JB6 C141 cells decreased the
expressions of the antiapoptotic proteins, Bcl-2 (panel A) and Bcl-xl (panel D), whereas the expression of the pro-apoptotic protein, Bax, was increased (panel B). A
representative blot is shown from three independent experiments with identical results. The ratio of Bax and Bcl-2 protein expression was determined from three
separate experiments by comparing the relative intensities of protein bands and shown as a mean ± SD (panel C). -Actin was used as an internal control to
monitor equal protein loading and transfer of proteins from the gel to the membranes after stripping them and reprobing them with the actin antibody.
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fibroblast cells (p53+/+) and p53-deficient fibroblast cells
(p53/). Our results showed that treatment of GSP signifi-
cantly induced apoptosis in p53+/+ cells, whereas p53/
cells failed to respond to GSP with the significant induction
of apoptosis (Figures 5 and 6). These results provide defi-
nitive evidence for the requirement of p53 in GSP-induced
apoptosis. Loss of tumor-suppressor gene function has
been correlated with amelioration of apoptosis and en-
hanced growth of tumors [48]. Conversely, Kaina [49] has
mentioned that mouse fibroblasts deficient for p53 were
more sensitive to induction of apoptosis due to the direct
involvement of p53 in DNA repair and attributed the apoptotic
Figure 8. Treatment of GSP increases the release of cytochrome c (panel A) and increases the expression of apoptotic protease–activating factor-1 (Apaf-1; panel
B), caspase 9 (panel C), and cleaved caspase 3 (panel D) in JB6 C141 cells. Antibody for caspase 3 specifically recognizes the cleaved products of caspase 3 (19
and 17 kDa), whereas the antibody for caspase 9 recognizes the cleaved (active) product at 35 kDa. A representative blot is shown from three independent
experiments with identical results. Cells were cultured and treatments were performed as described in Figure 4, and protein levels were analyzed by Western blot
analysis as described in the Materials and Methods section. Relative intensity of bands in each panel was determined and shown below each respective panel.
ND = not detectable.
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pathway to be dependent on the cell type. Our results as
well as the data of others with resveratrol [24] and caffeine
[25], however, also indicate that the probability of the induc-
tion of apoptosis through the p53 pathway is dependent both
on the cell type and the ability of the agent being tested to
induce apoptosis.
Experimental evidence suggests that several pathways
mediate p53-induced apoptosis, and one of these involves
the Bax protein. Bax is a p53 target and a proapoptotic
member of the Bcl-2 family of proteins [50,51]. The Bcl-2
family consists of both pro- and antiapoptotic members that
elicit opposing effects on mitochondria. Transcriptional acti-
vation by p53 of pro-apoptotic Bax can enhance the perme-
ability of the mitochondrial membrane, which in turn results in
the release of apoptogenic factors. Repression of anti-
apoptotic members such as Bcl-2 and Bcl-xl, which are
transcriptionally suppressed by p53 [52], preserves the in-
tegrity of the mitochondria. This blocks the release of these
soluble intermembrane factors, such as cytochrome c, that
activate the effectors of apoptosis [53]. In this study, we have
shown that GSP upregulates the pro-apoptotic Bax protein
and downregulates the antiapoptotic protein Bcl-2 in JB6
cells (Figure 7) and p53+/+ fibroblasts (Figure 9), but does
not do so in p53/ cells (Figure 9). More importantly, the
ratio of Bax/Bcl-2 protein expression is critical for apoptosis,
and the ratio of Bax/Bcl-2 dictates a cell’s susceptibility to
undergo apoptosis under experimental conditions [54–56].
Alteration in the Bax/Bcl-2 ratio causes the release of cyto-
chrome c from mitochondria into cytosol. Cytosolic cyto-
chrome c can bind to Apaf-1 and activate caspase 9 in the
apoptosomes in response to diverse inducers of cell death
[32–34]. Activation of caspase 9 leads to the activation of
caspase 3, which is one of the key mediators of p53-induced
apoptosis [34,56,57]. In our study, we found that treatment of
GSP results in an increase in Bax/Bcl-2 ratio in JB6 C141
cells (Figure 7), increased release of cytochrome c, activation
of Apaf-1 and caspase-9, and, finally, increased expression
of cleaved caspase 3 (Figure 8), which may result in in-
creased apoptosis in JB6 C141 cells. Similarly, treatment of
GSP to p53+/+ cells also results in several-fold increases in
Bax/Bcl-2 protein ratio, which may be responsible for making
these cells more susceptible for undergoing apoptosis, but
this effect was not observed in p53-deficient (p53/) cells
(Figure 9). These results provide evidence for the importance
of p53 and its phosphorylation product in GSP-induced
apoptosis. At the highest GSP dose levels, a small degree
of apoptosis was observed even in the p53/ cells. Although
we do not have experimental evidence to indicate that
Figure 9. Treatment of GSP decreases the expression of antiapoptotic proteins, Bcl-2 and Bcl-xl, and increases the expression of pro-apoptotic protein, Bax, in p53+/+
cells (left, panels A, B, and D). In p53-deficient cells (right panels), however, the levels of Bcl-2 (panel E) and Bax (panel F) remain almost unchanged. In contrast,
GSP also decreases Bcl-xl expression in p53/ (panel H). A representative blot is shown from three independent experiments with identical results. The ratio of Bax
and Bcl-2 protein expression in p53+/+ and p53/ fibroblasts was determined from three separate experiments and shown as mean ± SD (panels C and G). Cells
were cultured as described in Figure 5. After treatment with GSP for 24 hours, cells were harvested, lysates were prepared, and protein levels were analyzed by
Western blot analysis as described in the Materials and Methods section. -Actin was used as an internal control to monitor equal loading of the proteins.
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this is the case, it is possible that downregulation of Bcl-xl
could be responsible for the mild apoptosis observed in the
p53/ cells.
In conclusion, the data from our study indicate for the first
time that GSP-induced apoptosis in JB6 C141 cells occurs
primarily through a p53-dependent pathway and involves
its target proteins of the Bcl-2 family (i.e., Bax, Bcl-2) and
activation of caspase 3. Therefore, these findings suggest
that tumors retaining wild-type p53 will be more susceptible
to chemoprevention with GSP than tumors that express the
p53 mutants. In most human cancers, the p53 is mutated or
nonfunctional. In such scenario, GSP may not be beneficial
as a chemopreventive agent; however, it may be the possi-
bility that other apoptotic pathways may be involved with the
GSP treatment. This remains to be found out. Further, it
would prove beneficial to complement GSP with those
chemopreventive agents that are insensitive to p53 expres-
sion when p53 is absent or mutated. However, our data
suggest that GSP have the potential to be developed as a
pharmacologically safe agent to prevent cancer.
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